Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:1542 |
Name | head and neck carcinoma |
Definition | A head and neck cancer that has_material_basis_in epithelial cells and is located in the upper aerodigestive tract, including the lip, oral cavity (mouth), nasal cavity, paranasal sinuses, pharynx, and larynx. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer head and neck cancer head and neck carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR1 amp | Infigratinib | head and neck carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02723955 | Phase I | GSK3359609 GSK3359609 + Pembrolizumab | Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) | Completed | USA | NLD | ITA | FRA | ESP | CAN | AUS | 2 |
NCT03693014 | Phase II | A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors | Active, not recruiting | USA | 0 | |
NCT03727061 | Phase II | Cisplatin + Fluorouracil Carboplatin + Fluorouracil Pembrolizumab Cetuximab Nivolumab | Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer | Active, not recruiting | USA | 0 |
NCT04140526 | Phase Ib/II | ONC-392 ONC-392 + Pembrolizumab | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Recruiting | USA | AUS | 0 |
NCT05259319 | Phase I | Atezolizumab + Tiragolumab | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (IMMUNOs-SBRT) | Recruiting | FRA | 0 |